The Randomized And Controlled Non-inferiority Trial to Evaluate

Recruiting

99 years or below

All

50 participants needed

1 Location

Brief description of study

Prospective, multi-center, single-blind, randomized, controlled, noninferiority clinical trial. The trial will randomize approximately 446 subjects (at approximately 60 sites in the US and 18 sites outside the US) with symptomatic PAD due to stenoses of the femoral and/or popliteal arteries. Subjects meeting eligibility criteria will be randomized 1:1 to treatment with either the SurVeil DCB or the IN.PACT Admiral DCB, and followed for 60 months.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: TBD
Age: 99 years or below
Gender: All

Updated on 04 Aug 2024. Study ID: 830129

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

The Randomized And Controlled Non-inferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil Drug-Coated Balloon iN the Treatment of Subjects with Stenotic Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT Admiral Drug-Coated Balloon

Brief description of study

Eligibility of study

Find a site

Interested in the study